Guidance to Sponsors on How to Manage Clinical Trials during the COVID-19 Pandemic by European Union

Coronavirus management

The European Commission, the European Medicines Agency (EMA) and national Head of Medicines Agencies (HMA) have published new recommendations for sponsors on how to manage the conduct of clinical trials in the context of the coronavirus disease (COVID-19) pandemic. The impact of the pandemic on European health systems and more broadly on society, will make it necessary for sponsors to adjust how they manage clinical trials and the people who participate in these trials. It is an extensive guidance to sponsors in response to coronavirus pandemic.

Please read full article here

Download Guidance on the Management of Clinical Trials during the COVID-19 (Coronavirus) pandemic (PDF)

Latest Developments in Cancer

Comments

  • Susan ,

    Are there any clinical trials that stage 3 cancer patient how had Covid can join? Our friend is lung cancer and did well with corona virus.

  • Fiona Evans ,

    Hello Susan, Thank you for reaching out. Our Artificial Intelligence database will search through thousands of clinical trials to match patients to the best/most appropriate ones that they appear to be eligible for based off of their medical records, this will include reviewing past medical history, in this case would be Covid-19. We would be happy to assist your friend in finding clinical trials she may be eligible for, we are available by live chat, email at support@massivebio.com, and by phone at 844-627-7246.

  • Leave a Comment

    Your email address will not be published.

    Previous reading
    Guidance by NIH, CDC and FDA to Coronavirus Pandemic in the United States of America
    Next reading
    Our Response to Coronavirus Pandemic and Guidance to Cancer Patients